Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy

Hong Dai, Razack Abdullah, Xiaoqiu Wu, Fangfei Li, Yuan Ma*, Aiping Lu*, Ge Zhang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic cancer (PC) is one of the most lethal cancers with an almost 10% 5-year survival rate. Because PC is implicated in high heterogeneity, desmoplastic tumor-microenvironment, and inefficient drug-penetration, the chemotherapeutic strategy currently recommended for the treatment of PC has limited clinical benefit. Nucleic acid-based targeting therapies have become strong competitors in the realm of drug discovery and targeted therapy. A vast evidence has demonstrated that antibody-based or alternatively aptamer-based strategy largely contributed to the elevated drug accumulation in tumors with reduced systematic cytotoxicity. This review describes the advanced progress of antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), messenger RNA (mRNAs), and aptamer-drug conjugates (ApDCs) in the treatment of PC, revealing the bright application and development direction in PC therapy.

Original languageEnglish
Article number855474
JournalFrontiers in Cell and Developmental Biology
Volume10
DOIs
Publication statusPublished - 16 May 2022

Scopus Subject Areas

  • Developmental Biology
  • Cell Biology

User-Defined Keywords

  • antisense oligonucleotides
  • aptamer-drug conjugates
  • nucleic acid drugs
  • pancreatic cancer
  • small interfering RNAs
  • targeted therapy

Fingerprint

Dive into the research topics of 'Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy'. Together they form a unique fingerprint.

Cite this